Global Community

Acquisition of V TEX Corporation A franchise-defining semiconductor acquisition – With the ¥9.4bn acquisition of VTEX, KITZ becomes the clear global number two in semiconductor vacuum valves, with ~9% market share and the leading supplier within the booming Japanese Wafer Fab Equipment (WFE) supply chain. While the market may view this as a minor bolt-on acquisition, we believe it is a franchise-defining transaction of significant strategic importance.Read more

A healthcare device maker looks like a steady long-term add for someone trying to spread risk beyond big drug companies, helped by a recent buyout that broadens its brain-related tech offerings. The appeal is slow-and-steady growth and a long history of raising its payout, though the outlook isn’t flashy and some experts sound cautious.Read more

Novo Nordisk has gone from a steady insulin business to one of the key players behind the new wave of weight-loss and diabetes medicines, and the market may be overlooking how durable that shift is. Even with near-term pressure from pricing talks and production limits, wider insurance coverage, new product launches, and a deep pipeline could keep demand growing for years.Read more

Nova Ljubljanska Banka is aiming to grow its steady income and profits over the next few years, helped by tighter cost control and a plan to expand through deals. The big question is whether it can keep lending profits strong and navigate regional politics as it looks to deepen its presence in Croatia.Read more

Investment Thesis Palantir is positioning itself as a foundational AI deployment layer for governments and regulated industries. Unlike model providers or infrastructure hyperscalers, Palantir integrates AI into live operational workflows, with security controls, compliance guardrails, and auditability embedded into the platform.Read more

Cboe Global Markets just posted standout results, and the business looks like it’s getting stronger across options, global markets, currency trading, and market data. The bigger question is whether the stock price reflects how steady and defensible this exchange business can be, or if investors are still pricing it like a much riskier company.Read more

I have been an investor in PRCT since before IPO. The wild fluctuations in share price recently make no sense.Read more

Why the Market is Wrong About the ARS Pharma vs. Aquestive "Duopoly" Ticker: ARS Pharmaceuticals, Inc.Read more

Lion One Metals’ outlook changes dramatically if gold prices jump, turning its planned production into a much bigger cash generator. See how higher output and steady costs could reshape what the business might be worth—and what could derail that story.Read more